Creative Planning Acquires 93 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Creative Planning grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 6.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,632 shares of the medical research company’s stock after acquiring an additional 93 shares during the period. Creative Planning’s holdings in Bio-Rad Laboratories were worth $546,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Van ECK Associates Corp bought a new position in Bio-Rad Laboratories during the second quarter worth $180,040,000. First Eagle Investment Management LLC raised its stake in Bio-Rad Laboratories by 32,296.9% during the second quarter. First Eagle Investment Management LLC now owns 636,275 shares of the medical research company’s stock worth $173,773,000 after buying an additional 634,311 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Bio-Rad Laboratories by 64.4% during the second quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock worth $135,081,000 after buying an additional 193,700 shares during the last quarter. Select Equity Group L.P. raised its stake in Bio-Rad Laboratories by 26.2% during the second quarter. Select Equity Group L.P. now owns 649,522 shares of the medical research company’s stock worth $177,391,000 after buying an additional 134,856 shares during the last quarter. Finally, Earnest Partners LLC raised its stake in Bio-Rad Laboratories by 30.8% during the first quarter. Earnest Partners LLC now owns 514,906 shares of the medical research company’s stock worth $178,091,000 after buying an additional 121,272 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on BIO shares. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Royal Bank of Canada raised their price target on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target for the company. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $391.80.

Bio-Rad Laboratories Stock Up 1.5 %

Shares of NYSE BIO opened at $374.28 on Wednesday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.14 and a quick ratio of 4.52. The company has a 50-day moving average price of $335.10 and a 200-day moving average price of $309.32. Bio-Rad Laboratories, Inc. has a 1 year low of $262.12 and a 1 year high of $376.38. The stock has a market capitalization of $10.43 billion, a P/E ratio of -13.69 and a beta of 0.93.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The company had revenue of $649.70 million for the quarter, compared to analyst estimates of $628.18 million. During the same period last year, the firm earned $2.33 earnings per share. The firm’s revenue was up 2.8% on a year-over-year basis. On average, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 9.93 EPS for the current fiscal year.

Insider Activity at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 17.50% of the stock is owned by insiders.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.